A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting AntiviralNave Subjects with Chronic HCV Infection
||Male and Female Patients
|U.S. Govt. ID:
||Theresa Lukose: 212-305-6758 / firstname.lastname@example.org
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of study drugs Sofosbuvir, Velpatasvir and GS-9857 in comparison to Sofosbuvir and Velpatasvir in patients infected with HCV. Information about any side effects that may occur will also be collected.
This study is closed
Elizabeth Verna, MD
|Have you been diagnosed with Chronic HCV Infection?